BioToxTech Co

BioToxTech Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BioToxTech Co (086040.KQ) as of Nov 12, 2026 is -4.81 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -4.86 B KRW — a change of -1.02% (higher).

EBITDA

-4.81 BKRW

YoY

-1.02%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BioToxTech Co is 2025 -4.81 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BioToxTech Co was 2024 -4.86 B KRW. It decreases by -1.02% higher compared to the previous year.

The BioToxTech Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
150.62 M KRW
Jan 1, 2019
-1.05 B KRW
Jan 1, 2020
829.46 M KRW
Jan 1, 2021
4.45 B KRW
Jan 1, 2022
1.62 B KRW
Jan 1, 2023
-7.44 B KRW
Jan 1, 2024
-4.86 B KRW
Jan 1, 2025
-4.81 B KRW
The BioToxTech Co EBITDA history
YEAREBITDAYoY
-4.81 BKRW-1.02%
-4.86 BKRW-34.69%
-7.44 BKRW-559.44%
1.62 BKRW-63.57%
4.45 BKRW+435.97%
829.46 MKRW-179.04%
-1.05 BKRW-796.72%
150.62 MKRW-94.14%
2.57 BKRW+19.48%
2.15 BKRW-151.84%
-4.15 BKRW-7.51%
-4.49 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BioToxTech Co is -4.81 B KRW in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BioToxTech Co changed from -4.86 B KRW to -4.81 B KRW, representing a -1.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s BioToxTech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — BioToxTech Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — BioToxTech Co